July 23, 2012Date Released: 23 July 2012
MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Rob Dreicer, MD, Chair of Solid Tumor Oncology at Taussig Cancer Institute (TCI), has been appointed as Director for Clinical Trials for the Cancer Center, and in this capacity serves on the Executive Committee of the Case CCC and as chair of the Clinical Research Operations Committee (CROC). At TCI, Dr. Dreicer is also Deputy Director for Clinical Research. With this role, he is the TCI principal investigator for the N01 phase II clinical trials contract with NCI-CTEP and will be in charge of TCI interactions with cooperative groups. Dr. Dreicer will also be instrumental in clinical trial accrual, and, working together with Dr. Brian Rini, with TCI strategic planning for genomics. He will continue to lead Solid Tumor Oncology research.
Mikkael Sekeres, MD, MS has been appointed Vice Chair for Clinical Research at TCI. He will be in charge of clinical research in the region and affiliates; database development; conflict of interest; biostatistics; research compliance; clinical trial accrual and minority accrual; and operations. He will serve as the medical director for the TCI Clinical Trials Unit that interacts directly with the Case CCC Clinical Research Office. Dr. Sekeres will also be participating in genomic strategic planning.Notes from the Site Visit Preparation Retreat
The Cancer Center Annual Retreat was held July 10. We reviewed the nature of the NCI site visit and its goals. Two Programs gave preliminary presentations, and four cores were discussed. Images from the retreat are posted on our website.
Case CCC members can provide the following assistance for the upcoming site visit:
Recent scientific advances: Program leaders would like to highlight recent scientific advances, preferably in the context of collaboration aligned with the scientific focus areas of the program. If you have a recent advance, publication or grant please email or discuss with your program leader. They will be preparing 10 minute presentations for the EAB on September 7.
Clinical trial accrual: We will provide an update of accrual through September 30, 2012. Thus, your clinical research efforts over the next three months really matter! Please take the opportunity to discuss clinical trials with your patients.
New collaborative efforts: Please let program leaders know about new grant submissions, papers published, new clinical trials developed, even at the LOI stage, and new collaborations.
Journal Covers: We are collecting images of journal covers featuring Cancer Center member research from the past five years. Please send an image of the cover to Gillian Todd.
The EAB meeting is set for September 7 in Thwing, and will be a full rehearsal for the site visit. A number of individuals not presenting will be asked to attend individual program presentations to support the science presented. The roster for the site visit will be circulated the first week of October.Case CCC Community Advisory Board
The Case CCC recently named a community advisory board to guide the Cancer Center in addressing cancer care disparities in our minority and underserved populations. The Board partners with the community and the Cancer Center. Among its goals are better understanding of the underlying factors contributing to disparities, and developing meaningful education programs to underscore the importance of preventive care and screening to detect cancer at an early stage. Also emphasized will be cancer care options and the importance of clinical research in developing new and more effective treatments.
The Community Advisory Board recently represented the Cancer Center at Brother to Brother Health and Wellness Rap Session for Cuyahoga Metropolitan Housing Authority (CMHA) men, and publicized the lung cancer screening program at Cleveland Clinic and University Hospitals. Upcoming events include other community programs where we can educate the public on the importance of early detection and prevention care for cancer.Notes from the NCI Board of Scientific Advisors Meeting
The NCI Board of Scientific Advisors met on June 25. During this public meeting, the board reviewed key decision point initiatives at the NCI. Those of note to Cancer Center members include:
Establishment of an AIDS malignancies task force for NCI: I have been asked to join this subcommittee to review opportunities to expand world-wide and NCI cancer center based efforts in the area of HIV-associated malignancies. We will evaluate current research and database activities, demographics of cancer risk and the role of ongoing HIV infection, and interactions between CFARs and Cancer Centers. Given our initiatives in these areas and ongoing efforts in Uganda, this is an ideal opportunity to increase our visibility in this research area.
Bullet points from the NCI
CASE CCC IN THE NEWS
Genetic Aberrations Seen as Path to Stop Colon Cancer
Hope for brain cancer treatment lies within vaccine being tested at Ridgewood hospital
ANNOUNCEMENTSMukesh Jain, MD to Lead the American Society for Clinical Investigation
Dr. Mukesh Jain has been elected Vice President of the American Society for Clinical Investigation (ASCI). Following his tenure as Vice President of ASCI, Dr. Jain will advance to President Elect, then President in successive years. Established in 1908, the ASCI is one of the nation's oldest and most respected medical honor societies, and has more than 3,000 members.
FUNDING OPPORTUNITIESDOD Broad Agency Announcement for Extramural Biomedical Research and Development
The United States Special Operations Command (USSOCOM)seeks novel biomedical solutions to preserve the high level of performance and save the lives of Special Operations Forces (SOF) in field environments. Any projects proposed must be unique to the requirements of SOF who typically conduct combat operations in austere, remote locations without timely access to medical evacuation or elevated levels of medical care. It is these far-forward and/or isolated operations that make SOF medicine unique and result in material solutions characterized by ruggedness, light weight, small volume, and low power requirements. USSOCOM is also interested in research that will lead to improved techniques and procedures that do not necessarily require new material.
Pre-proposal Deadline: August 3
The Foundation for Women's Cancer is accepting applications for its research grants and awards program. Awards will be given to support ovarian cancer research. The Foundation will fund the best project applications, with priority given to young investigators. The Foundation will accept one application per person per year.
Abstracts Deadline: August 13
The AACR-Kure It Grant for Kidney Cancer Researchrepresents a joint effort to promote and support innovative cancer research. This grant is available to independent investigators to develop and study new ideas and approaches that have direct application and relevance to kidney cancer patients.
Applications are invited from researchers currently in the field as well as from investigators with experience in other areas of cancer research who have promising ideas or research approaches that can be applied to kidney cancer research.
Deadline: August 21Burroughs Wellcome Fund
The Burroughs Wellcome Fund is accepting applications for two programs that are designed for advanced postdoctoral scientists to help make the transition to a faculty appointment:
The American Association for Cancer Research is currently accepting nominations for the Pezcoller Foundation-AACR International Award for Cancer Research. This award recognizes an individual scientist or co-nominated scientists of international renown who have made a major scientific discovery in basic or translational cancer research, and whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer. The recipient of the Pezcoller Foundation-AACR International Award for Cancer Research will receive an unrestricted grant of €75,000 and a commemorative plaque. In addition, he or she will receive full support to attend the AACR Annual Meeting 2013, to be held April 6-10 in Washington, D.C., and will give a 50-minute award lecture at the Annual Meeting.
Deadline: September 12Robert Wood Johnson Foundation Human Capital Programs
The Robert Wood Johnson Foundation (RWJF) has released a call for proposals to support new projects in Human Capital:
The Clinical and Translational Science Collaborative KL2 Training Program seeks candidates to fill Clinical Research Scholar positions. These positions will be available in July 2013. The training program is a component of the Cleveland CTSC and is funded by the NIH.
Deadline: October 22
**All events are open to anyone interested in attending
Hematology and Oncology Division Research Conference
Cancer Center Research in Progress will resume in September
Cancer Center Seminar Series will resume in September.
Taussig Cancer Institute Grand Rounds will resume in September
Hematology/Oncology Fellows Conference/Curriculum Series
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Developmental Therapeutics Program Retreat: Cancer Drug Development at the Case Comprehensive Cancer Center
Second Annual Imaging Solutions in Cancer Management: A Case-Based Conference
National GvHD Health Symposium
ADDITIONAL UPCOMING SEMINARS & EVENTS
Ninth International Conference of the Society for Integrative Oncology
Biennial Science of Global Prostate Cancer Disparities conference
Pacific Symposium on Biocomputing 2013
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Alex's Lemonade Stand Foundation Bridge Grant
Oncology Nursing Society Foundation Advancing Care through Science Conference Scholarship
NIH BULLETIN – Notices and Funding Opportunities
Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (P50) (RFA-DA-13-003)
Physical activity and weight control interventions among cancer survivors: Effects on biomarkers of prognosis and survival (R01) (PAR-12-228)
Physical activity and weight control interventions among cancer survivors: Effects on biomarkers of prognosis and survival (R21) (PAR-12-229)
Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations (R01)(PA-10-035)
Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01)(PA-10-025)
Epigenetic Approaches in Cancer Epidemiology (R01)(PA-10-031)
Epigenetic Approaches in Cancer Epidemiology (R21)(PA-10-032)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.